期刊
ONCOTARGET
卷 8, 期 54, 页码 93117-93130出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.21861
关键词
pancreatic cancer; proteomics; diagnostic biomarker; multimarker panel; multiple reaction monitoring
资金
- Collaborative Genome Program for Fostering New Post-Genome Industry [NRF-2017M3C9A5031597]
- National Research Foundation [2011-0030740]
- Industrial Strategic Technology Development Program [10079271]
- Korea Health Technology RD Project [HI16C2037, HI14C2640]
- SK Telecom Research Fund
Due to its high mortality rate and asymptomatic nature, early detection rates of pancreatic ductal adenocarcinoma (PDAC) remain poor. We measured 1000 biomarker candidates in 134 clinical plasma samples by multiple reaction monitoring-mass spectrometry (MRM-MS). Differentially abundant proteins were assembled into a multimarker panel from a training set (n = 684) and validated in independent set (n = 318) from five centers. The level of panel proteins was also confirmed by immunoassays. The panel including leucine-rich alpha-2 glycoprotein (LRG1), transthyretin (TTR), and CA19-9 had a sensitivity of 82.5% and a specificity of 92.1%. The triple-marker panel exceeded the diagnostic performance of CA19-9 by more than 10% (AUC(CA19-9) = 0.826, AUC(panel) = 0.931, P < 0.01) in all PDAC samples and by more than 30% (AUC(CA19-9) = 0.520, AUC(panel) = 0.830, P < 0.001) in patients with normal range of CA19-9 (< 37U/mL). Further, it differentiated PDAC from benign pancreatic disease (AUC(CA19-9) = 0.812, AUC(panel) = 0.892, P < 0.01) and other cancers (AUC(CA19-9) = 0.796, AUC(panel) = 0.899, P < 0.001). Overall, the multimarker panel that we have developed and validated in large-scale samples by MRM-MS and immunoassay has clinical applicability in the early detection of PDAC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据